Sinus and Mastoid Procedures without CC/MCC DRG Reimbursement

DRG 136 encompasses inpatient admissions for sinus and mastoid procedures without a Major Complication or Comorbidity and without a Complication or Comorbidity and defines the clinical scope of cases eligible for a standard payment weight. It matters for inpatient reimbursement because it standardizes payment for these procedures under the prospective payment system and is sensitive to coding of procedures and secondary diagnoses that could change the Diagnosis-Related Group and payment.

DRG 136 Overview

DRG 136 covers inpatient admissions for sinus and mastoid procedures without a Major Complication or Comorbidity and without a Complication or Comorbidity. It includes operative management of chronic or acute sinus and mastoid disease when the admission does not carry higher-severity secondary diagnoses. This Diagnosis-Related Group matters for Medicare payment because it groups similar resource use and determines the prospective payment amount for hospitals under the inpatient prospective payment system. Accurate coding and documentation of procedures and secondary diagnoses affect assignment to this Diagnosis-Related Group and the resulting Medicare reimbursement.

Trials evaluating minimally invasive surgical techniques versus traditional open sinus or mastoid procedures: these studies compare operative approaches (endoscopic sinus surgery, balloon sinuplasty, or transmastoid endoscopic techniques) in patients with chronic rhinosinusitis or chronic otitis media requiring operative intervention without major comorbidity. They enroll mostly otherwise healthy adults and focus on intraoperative metrics, short-term complication rates, operative time, and early symptom relief to determine whether less invasive approaches reduce length of stay and perioperative resource use. Results are directly relevant to hospitals and payers because reductions in complications, operative time, and LOS can lower episode costs and influence DRG resource utilization.
Comparative effectiveness trials of perioperative antibiotic and steroid protocols to reduce recurrence and readmission: these randomized or pragmatic studies examine different antibiotic stewardship strategies, topical or systemic steroid regimens, or combinations thereof in patients undergoing sinus or mastoid surgery who do not have major CC/MCC. The objective is to measure postoperative infection rates, need for revision procedures, and unplanned clinic or ED visits within 30–90 days, identifying protocols that optimize outcomes while minimizing unnecessary antimicrobial use. Findings inform clinical pathways, discharge instructions, and payer policies by highlighting strategies that decrease readmissions and downstream costs associated with postoperative complications.
Longitudinal outcomes and quality-of-life studies after index sinus or mastoid procedures focused on return-to-function and resource utilization: these observational cohort studies follow patients after discharge to measure symptom control, hearing outcomes (for mastoid surgery), sinonasal quality-of-life scores, use of outpatient services, and rates of revision surgery over 1–2 years. They typically include PROMs and healthcare utilization endpoints to capture durable effectiveness of the index hospitalization and identify predictors of high-cost post-acute care (e.g., comorbid allergic disease or smoking). This research helps providers and payers understand long-term value of the initial procedure, guide case selection for inpatient surgery under this DRG, and design follow-up care pathways that reduce preventable downstream spending.

Trials evaluating minimally invasive surgical techniques versus traditional open sinus or mastoid procedures: these studies compare operative approaches (endoscopic sinus surgery, balloon sinuplasty, or transmastoid endoscopic techniques) in patients with chronic rhinosinusitis or chronic otitis media requiring operative intervention without major comorbidity. They enroll mostly otherwise healthy adults and focus on intraoperative metrics, short-term complication rates, operative time, and early symptom relief to determine whether less invasive approaches reduce length of stay and perioperative resource use. Results are directly relevant to hospitals and payers because reductions in complications, operative time, and LOS can lower episode costs and influence DRG resource utilization.
Comparative effectiveness trials of perioperative antibiotic and steroid protocols to reduce recurrence and readmission: these randomized or pragmatic studies examine different antibiotic stewardship strategies, topical or systemic steroid regimens, or combinations thereof in patients undergoing sinus or mastoid surgery who do not have major CC/MCC. The objective is to measure postoperative infection rates, need for revision procedures, and unplanned clinic or ED visits within 30–90 days, identifying protocols that optimize outcomes while minimizing unnecessary antimicrobial use. Findings inform clinical pathways, discharge instructions, and payer policies by highlighting strategies that decrease readmissions and downstream costs associated with postoperative complications.
Longitudinal outcomes and quality-of-life studies after index sinus or mastoid procedures focused on return-to-function and resource utilization: these observational cohort studies follow patients after discharge to measure symptom control, hearing outcomes (for mastoid surgery), sinonasal quality-of-life scores, use of outpatient services, and rates of revision surgery over 1–2 years. They typically include PROMs and healthcare utilization endpoints to capture durable effectiveness of the index hospitalization and identify predictors of high-cost post-acute care (e.g., comorbid allergic disease or smoking). This research helps providers and payers understand long-term value of the initial procedure, guide case selection for inpatient surgery under this DRG, and design follow-up care pathways that reduce preventable downstream spending.

OpenPayer

Summary & Overview

Sinus and Mastoid Procedures without CC/MCC: Inpatient Reimbursement Overview

DRG 136 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes